Compare Amgen, Inc. (AMGN) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Manhattan Associates Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Manhattan Associates Inc trades at $155.41 (market cap $9.17B). The key difference: Amgen, Inc. is far larger — about 21.4× Manhattan Associates Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| AMGN | MANH | |
|---|---|---|
Market Cap | $196.12B | $9.17B |
Sector | Health | Technology |
52-Week High | $388.16 | $227.94 |
52-Week Low | $271.18 | $120.88 |
Enterprise Value | $241.41B | $9.00B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MANH trades at $154.9, down 1.1% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. Recent news is dominated by an ongoing legal investigation into fiduciary duties by directors and officers.
The outlook is supported by a strong analyst consensus 'Buy' rating and a $192.80 price target, implying significant upside. Key risks include the legal investigation's outcome and potential pressure on valuation multiples, which are elevated. Revenue stability and high ROE of 96.24% underpin the fundamental case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
